NC Medial Research Inc
This is an initial Phase1/2 dose-finding, randomized, multi-center study to evaluate the safety and tolerability of NCS-01 in patients with acute ischemic stroke. All patients will be randomized within 48 hours of stroke onset. This study will be conducted in 2 stages.
Ischemic Stroke
NCS-01
Phase 1
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 16 participants |
Masking: | Quadruple |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2 Randomized Study to Evaluate the Safety and Tolerability of Intracarotid Artery Administration of NCS-01 in Patients With Acute Ischemic Stroke |
Actual Study Start Date : | February 27, 2020 |
Estimated Primary Completion Date : | October 2027 |
Estimated Study Completion Date : | October 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: NCS-01 human bone marrow derived cells |
Biological: NCS-01 |
Sham Comparator: sham sham procedure |
Biological: NCS-01 |
Ages Eligible for Study: | 18 Years to 85 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
University of Miami
Miami, Florida, United States, 33136
Recruiting
The University of Texas
Houston, Texas, United States, 77030